ASTRAZENECA PLC-SPONS ADR (AZN) Stock Fundamental Analysis

NYSE:AZN • US0463531089

208.45 USD
+4.47 (+2.19%)
At close: Feb 27, 2026
208.45 USD
0 (0%)
After Hours: 2/27/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, AZN scores 6 out of 10 in our fundamental rating. AZN was compared to 192 industry peers in the Pharmaceuticals industry. AZN scores excellent on profitability, but there are some minor concerns on its financial health. AZN has a decent growth rate and is not valued too expensively. AZN also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • AZN had positive earnings in the past year.
  • AZN had a positive operating cash flow in the past year.
  • Each year in the past 5 years AZN has been profitable.
  • Each year in the past 5 years AZN had a positive operating cash flow.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • AZN has a Return On Assets of 8.96%. This is amongst the best in the industry. AZN outperforms 90.63% of its industry peers.
  • Looking at the Return On Equity, with a value of 21.01%, AZN belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 13.63%, AZN belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.96%.
  • The 3 year average ROIC (12.48%) for AZN is below the current ROIC(13.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • With an excellent Profit Margin value of 17.41%, AZN belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
  • AZN's Profit Margin has improved in the last couple of years.
  • AZN has a Operating Margin of 23.86%. This is amongst the best in the industry. AZN outperforms 91.15% of its industry peers.
  • In the last couple of years the Operating Margin of AZN has grown nicely.
  • AZN's Gross Margin of 81.31% is amongst the best of the industry. AZN outperforms 85.94% of its industry peers.
  • In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
  • AZN has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AZN has more shares outstanding
  • The debt/assets ratio for AZN has been reduced compared to a year ago.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • AZN has an Altman-Z score of 3.96. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of AZN (3.96) is better than 71.35% of its industry peers.
  • The Debt to FCF ratio of AZN is 3.42, which is a good value as it means it would take AZN, 3.42 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.42, AZN belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
  • A Debt/Equity ratio of 0.55 indicates that AZN is somewhat dependend on debt financing.
  • The Debt to Equity ratio of AZN (0.55) is worse than 63.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.96
ROIC/WACC1.5
WACC9.1%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that AZN may have some problems paying its short term obligations.
  • AZN's Current ratio of 0.94 is on the low side compared to the rest of the industry. AZN is outperformed by 85.94% of its industry peers.
  • AZN has a Quick Ratio of 0.94. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AZN's Quick ratio of 0.72 is on the low side compared to the rest of the industry. AZN is outperformed by 83.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.57%, which is quite good.
  • Measured over the past years, AZN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.91% on average per year.
  • Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
  • Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.40% on average per year.
  • The Revenue is expected to grow by 6.77% on average over the next years.
EPS Next Y15.32%
EPS Next 2Y13.49%
EPS Next 3Y12.9%
EPS Next 5Y12.4%
Revenue Next Year6.85%
Revenue Next 2Y6.51%
Revenue Next 3Y6.3%
Revenue Next 5Y6.77%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.56, AZN is valued on the expensive side.
  • AZN's Price/Earnings ratio is rather cheap when compared to the industry. AZN is cheaper than 81.25% of the companies in the same industry.
  • AZN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.10, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 19.57, which indicates a rather expensive current valuation of AZN.
  • AZN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AZN is cheaper than 78.13% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AZN to the average of the S&P500 Index (28.06), we can say AZN is valued slightly cheaper.
Industry RankSector Rank
PE 22.56
Fwd PE 19.57
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • AZN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AZN is cheaper than 82.29% of the companies in the same industry.
  • 79.69% of the companies in the same industry are more expensive than AZN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 37.27
EV/EBITDA 17.19
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.90% in the coming years.
PEG (NY)1.47
PEG (5Y)1.26
EPS Next 2Y13.49%
EPS Next 3Y12.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • AZN has a Yearly Dividend Yield of 1.60%.
  • Compared to an average industry Dividend Yield of 1.07, AZN pays a better dividend. On top of this AZN pays more dividend than 91.15% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, AZN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.6%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 3.33%.
  • AZN has paid a dividend for at least 10 years, which is a reliable track record.
  • AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.33%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
  • AZN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.62%
EPS Next 2Y13.49%
EPS Next 3Y12.9%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (2/27/2026, 8:04:00 PM)

After market: 208.45 0 (0%)

208.45

+4.47 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners49.17%
Inst Owner Change0.95%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap323.16B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts82.94
Price Target202.76 (-2.73%)
Short Float %0.26%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield 1.6%
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-1.5%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)0.45%
Min EPS beat(4)-7.49%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.6%
EPS beat(12)7
Avg EPS beat(12)1.6%
EPS beat(16)11
Avg EPS beat(16)2.81%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)-0.26%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)-0.26%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-0.82%
PT rev (1m)107.33%
PT rev (3m)117.83%
EPS NQ rev (1m)98.7%
EPS NQ rev (3m)205.32%
EPS NY rev (1m)100.26%
EPS NY rev (3m)99.52%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0.99%
Revenue NY rev (3m)1.59%
Valuation
Industry RankSector Rank
PE 22.56
Fwd PE 19.57
P/S 5.5
P/FCF 37.27
P/OCF 22.17
P/B 6.64
P/tB N/A
EV/EBITDA 17.19
EPS(TTM)9.24
EY4.43%
EPS(NY)10.65
Fwd EY5.11%
FCF(TTM)5.59
FCFY2.68%
OCF(TTM)9.4
OCFY4.51%
SpS37.89
BVpS31.39
TBVpS-6.72
PEG (NY)1.47
PEG (5Y)1.26
Graham Number80.79
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.96
F-Score7
WACC9.1%
ROIC/WACC1.5
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
EPS Next Y15.32%
EPS Next 2Y13.49%
EPS Next 3Y12.9%
EPS Next 5Y12.4%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year6.85%
Revenue Next 2Y6.51%
Revenue Next 3Y6.3%
Revenue Next 5Y6.77%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year23.4%
EBIT Next 3Y12.45%
EBIT Next 5Y11.39%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC-SPONS ADR / AZN FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 5 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.


How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for AZN stock?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 22.56 and the Price/Book (PB) ratio is 6.64.


What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 15.32% in the next year.